Patients with completely resected nongenitourinary low‐risk embryonal rhabdomyosarcoma are candidates for reduced duration low‐intensity chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34497
Abstract: The survival of patients with localized embryonal rhabdomyosarcoma (RMS) completely resected at diagnosis is greater than 90%. Most patients have paratesticular, uterine, or vaginal RMS, limiting specific analyses of RMS localized in other anatomic regions.… read more here.
Keywords: patients completely; completely resected; nongenitourinary low; embryonal rhabdomyosarcoma ... See more keywords
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-018-2223-z
Abstract: Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m2/day. Preclinical data in IC-treated tumor-bearing mice with low tumor burden documented striking… read more here.
Keywords: melanoma; patients completely; group; hu14 il2 ... See more keywords
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0533-3
Abstract: BackgroundRetrospective studies suggest that low molecular weight heparin may delay the development of metastasis in patients with resected NSCLC.MethodsMulticentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive… read more here.
Keywords: patients completely; completely resected; chemotherapy without; study ... See more keywords